Research programme: adenosine A2A receptor agonists - Clinical Data
Alternative Names: ATL 1222; ATL908Latest Information Update: 18 May 2020
Price :
$50 *
At a glance
- Originator Adenosine Therapeutics LLC
- Developer PGxHealth
- Class
- Mechanism of Action Adenosine A2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in USA
- 01 Jul 2014 Forest Laboratories has been acquired by Actavis Inc